An exceptional response to (177)LuPSMA undermined by neuroendocrine transformation

Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilinski, Pretoria, Webb, Myles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596197/
https://www.ncbi.nlm.nih.gov/pubmed/33145175
http://dx.doi.org/10.1016/j.eucr.2020.101467
Descripción
Sumario:Approximately 25% of patients who have undergone extensive systemic therapy for advanced metastatic castration-resistant prostate cancer (mCRPC) develop treatment associated neuroendocrine prostate cancer (NEPC). (177)Lu-prostate specific membrane antigen (-PSMA) is an emerging alternative therapy for mCRPC patients who have exhausted other systemic therapy options; however, cells with neuroendocrine differentiation do not express PSMA and are not affected by this treatment. This case highlights an exceptional response of skeletal metastases to 177LuPSMA that is undermined by neuroendocrine transformation in the liver.

Ejemplares similares